CN104350057A - 用作治疗剂的螺-羟吲哚化合物的不对称合成 - Google Patents

用作治疗剂的螺-羟吲哚化合物的不对称合成 Download PDF

Info

Publication number
CN104350057A
CN104350057A CN201380030552.0A CN201380030552A CN104350057A CN 104350057 A CN104350057 A CN 104350057A CN 201380030552 A CN201380030552 A CN 201380030552A CN 104350057 A CN104350057 A CN 104350057A
Authority
CN
China
Prior art keywords
formula
compound
enantiomer
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380030552.0A
Other languages
English (en)
Chinese (zh)
Inventor
孙绍毅
傅健民
苏鲁旦·乔德亨瑞
伊凡·威廉·希穆恩
迈克尔·爱德华·格里姆伍德
泰里克·苏黑·曼索尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenon Pharmaceuticals Inc
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of CN104350057A publication Critical patent/CN104350057A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201380030552.0A 2012-04-12 2013-03-11 用作治疗剂的螺-羟吲哚化合物的不对称合成 Pending CN104350057A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261623336P 2012-04-12 2012-04-12
US61/623,336 2012-04-12
PCT/US2013/030219 WO2013154712A1 (en) 2012-04-12 2013-03-11 Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610207838.7A Division CN105753877A (zh) 2012-04-12 2013-03-11 用作治疗剂的螺-羟吲哚化合物的不对称合成

Publications (1)

Publication Number Publication Date
CN104350057A true CN104350057A (zh) 2015-02-11

Family

ID=47902379

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380030552.0A Pending CN104350057A (zh) 2012-04-12 2013-03-11 用作治疗剂的螺-羟吲哚化合物的不对称合成
CN201610207838.7A Pending CN105753877A (zh) 2012-04-12 2013-03-11 用作治疗剂的螺-羟吲哚化合物的不对称合成

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610207838.7A Pending CN105753877A (zh) 2012-04-12 2013-03-11 用作治疗剂的螺-羟吲哚化合物的不对称合成

Country Status (14)

Country Link
US (2) US9487535B2 (cg-RX-API-DMAC7.html)
EP (1) EP2838902B1 (cg-RX-API-DMAC7.html)
JP (1) JP6195609B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150002794A (cg-RX-API-DMAC7.html)
CN (2) CN104350057A (cg-RX-API-DMAC7.html)
AU (1) AU2013246485A1 (cg-RX-API-DMAC7.html)
CA (1) CA2869547A1 (cg-RX-API-DMAC7.html)
EA (1) EA201491854A1 (cg-RX-API-DMAC7.html)
ES (1) ES2714314T3 (cg-RX-API-DMAC7.html)
HK (3) HK1205114A1 (cg-RX-API-DMAC7.html)
IL (1) IL235006A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014012266A (cg-RX-API-DMAC7.html)
WO (1) WO2013154712A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201407334B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150882T1 (hr) 2008-10-17 2015-09-25 Xenon Pharmaceuticals Inc. Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
PE20170202A1 (es) 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
RU2596488C2 (ru) 2010-02-26 2016-09-10 Ксенон Фармасьютикалз Инк. Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
KR20150002794A (ko) 2012-04-12 2015-01-07 제논 파마슈티칼스 인크. 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
WO2017180248A1 (en) * 2016-04-15 2017-10-19 William Marsh Rice University Enantioenriched viridicatumtoxin b analogs
EP3468545B1 (en) 2016-06-08 2026-08-05 President and Fellows of Harvard College Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, rett syndrome, and fragile x syndrome
WO2017218920A1 (en) 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Asymmetric synthesis of funapide
CN109311905A (zh) * 2016-06-16 2019-02-05 泽农医药公司 螺-吲哚酮化合物的固态形式
CN108395438A (zh) * 2018-04-03 2018-08-14 陕西科技大学 一类具有抗菌活性的靛红母核螺环化合物及其合成方法
WO2019226808A1 (en) 2018-05-22 2019-11-28 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
EP3801512A4 (en) 2018-05-29 2022-01-19 President and Fellows of Harvard College COMPOSITIONS AND METHODS TO REDUCE TACTILE DYSFUNCTION, ANXIETY AND SOCIAL DISABILITIES
US12077512B2 (en) 2019-03-25 2024-09-03 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
CN116057045B (zh) 2020-06-05 2026-06-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶抑制剂
US12552808B2 (en) 2020-09-03 2026-02-17 Amgen Inc. Diol desymmetrization by nucleophilic aromatic substitution

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101184761A (zh) * 2005-04-11 2008-05-21 泽农医药公司 螺-吲哚酮化合物及其作为治疗剂的用途
WO2011002708A1 (en) * 2009-06-29 2011-01-06 Xenon Pharmaceuticals Inc. Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
WO2011047174A1 (en) * 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
CN102256983A (zh) * 2008-10-17 2011-11-23 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723459A (en) 1971-04-23 1973-03-27 Mc Neil Labor Inc 2-oxospiro (indoline -3,4{40 -thiochroman) derivatives
JPS6130554A (ja) 1984-07-23 1986-02-12 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤
DE3608088C2 (de) 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
JP2716986B2 (ja) 1987-07-17 1998-02-18 シエーリング アクチエンゲゼルシヤフト 9‐ハロゲン‐(z)‐プロスタグランジン誘導体、その製法及び薬剤としてのその使用
US5314685A (en) 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
NO317155B1 (no) 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
ATE237587T1 (de) 1997-02-10 2003-05-15 Ono Pharmaceutical Co 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten
WO1999033794A1 (en) 1997-12-25 1999-07-08 Ono Pharmaceutical Co., Ltd. φ-CYCLOALKYL-PROSTAGLANDIN E2 DERIVATIVES
JP4087938B2 (ja) 1998-02-04 2008-05-21 高砂香料工業株式会社 ヒノキチオ−ル類の分岐サイクロデキストリン包接化合物からなる抗菌剤およびそれを含有する組成物
US6235780B1 (en) 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
JPWO2005035498A1 (ja) 2003-10-08 2006-12-21 住友製薬株式会社 含窒素二環性化合物の摂食調節剤としての用途
JP2007536283A (ja) 2004-05-05 2007-12-13 ユニバイオスクリーン エス.アー. ナフタルイミド誘導体、それらの製造方法、およびそれらの医薬組成物
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
SI1924264T1 (sl) 2005-09-01 2013-12-31 F. Hoffmann-La Roche Ag Diaminopirimidini kot modulatorji p2x3 in p2x2/3
WO2007081895A2 (en) * 2006-01-09 2007-07-19 Merck & Co., Inc. Preparation of substituted 2-hydroxygibba-1(10a), 2, 4, 4b-tetraen-6-ones
WO2008046049A1 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2008046087A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro compounds and their uses as therapeutic agents
EP2073806B1 (en) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
BRPI0719166A2 (pt) 2006-10-12 2014-06-03 Xenon Pharmaceuticals Inc Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos
GB0704846D0 (en) 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
US20110269788A1 (en) 2008-12-29 2011-11-03 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
US8295257B2 (en) 2009-03-13 2012-10-23 Telcordia Technologies, Inc. Scalable disruptive-resistant communication method
WO2010132352A2 (en) * 2009-05-11 2010-11-18 Xenon Pharmaceuticals Inc. Spiro compounds and their use as therapeutic agents
US20110086899A1 (en) 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
RU2596488C2 (ru) 2010-02-26 2016-09-10 Ксенон Фармасьютикалз Инк. Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
KR20150002794A (ko) 2012-04-12 2015-01-07 제논 파마슈티칼스 인크. 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101184761A (zh) * 2005-04-11 2008-05-21 泽农医药公司 螺-吲哚酮化合物及其作为治疗剂的用途
CN102256983A (zh) * 2008-10-17 2011-11-23 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
WO2011002708A1 (en) * 2009-06-29 2011-01-06 Xenon Pharmaceuticals Inc. Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
WO2011047174A1 (en) * 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ECKEHARD VOLKER DEHMLOW 等: "Monodeazacinchona Alkaloid Derivatives: Synthesis and Preliminary Applications as Phase-Transfer Catalysts", 《EUR. J. ORG. CHEM.》 *
TAKASHI OOI 等: "Recent Advances in Asymmetric Phase-Transfer Catalysis", 《ANGEWANDTE CHEMIE INTERNATIONAL EDITION》 *

Also Published As

Publication number Publication date
KR20150002794A (ko) 2015-01-07
IL235006A0 (en) 2014-12-31
WO2013154712A1 (en) 2013-10-17
EP2838902A1 (en) 2015-02-25
US20130274483A1 (en) 2013-10-17
US9487535B2 (en) 2016-11-08
ZA201407334B (en) 2017-05-31
HK1226389A1 (zh) 2017-09-29
JP2015516389A (ja) 2015-06-11
EA201491854A1 (ru) 2015-03-31
US20170066777A1 (en) 2017-03-09
AU2013246485A1 (en) 2014-10-16
ES2714314T3 (es) 2019-05-28
CN105753877A (zh) 2016-07-13
HK1205114A1 (en) 2015-12-11
JP6195609B2 (ja) 2017-09-13
CA2869547A1 (en) 2013-10-17
MX2014012266A (es) 2014-12-05
EP2838902B1 (en) 2018-12-05
HK1205113A1 (en) 2015-12-11

Similar Documents

Publication Publication Date Title
JP6195609B2 (ja) 治療剤として有用なスピロ−オキソインドール化合物の不斉合成
TWI790264B (zh) 雜環化合物及其用途
ES2934785T3 (es) Compuestos antibacterianos y usos de los mismos
CA2849168A1 (en) Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
US20060247439A1 (en) Mchir antagonists
HU222724B1 (hu) Eljárás 3-amino-2-fenil-piperidin elżállítására
WO2013104257A1 (zh) 多环类衍生物、其制备方法及其在医药上的应用
CA3172478A1 (en) Bcl-2 inhibitor
WO2009149258A2 (en) Crystalline form of 6-[(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
CN116670124A (zh) 被取代的哌啶类化合物及相关治疗方法
JP2001521529A (ja) 置換へテロ芳香環5−ht▲下1f▼アゴニスト
CN107530349A (zh) 作为a2b拮抗剂的黄嘌呤取代的炔基氨基甲酸酯/反式氨基甲酸酯
WO2000000490A2 (en) 5-ht1f agonists
RU2102392C1 (ru) Пиперидилметилзамещенные производные хромана и их соли с неорганическими кислотами
EP2297148A1 (fr) NOUVEAUX DERIVES DE (PIPERAZINYL PONTE)-1-ALCANONE ET LEUR UTILISATION COMME INHIBITEURS DE p75
US6608079B1 (en) Indole derivatives and their use as 5-HT1F agonists
CN103328492A (zh) 作为受体调节剂具有疗效的新型化合物
JPWO2014181788A1 (ja) α−置換グリシンアミド誘導体
EA017802B1 (ru) Азабициклоалкановые производные, их получение и их применение в терапии
CN119768169A (zh) 取代的稠合二环化合物以及相关的治疗方法
CA3191456A1 (en) Novel compounds having inhibitory activity on prostaglandin e2 receptor and uses thereof
DE4227791A1 (de) Pyrrolo (2,3c)-pyridinderivate, deren herstellung und verwendung in arzneimitteln
JP2002509145A (ja) 置換β,γ−縮合ラクトン
CN119301119A (zh) 新型茚酮衍生物及其用途
JP2016094407A (ja) 新規なtrpm8阻害薬

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1205113

Country of ref document: HK

AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20180713

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1205113

Country of ref document: HK